Document is current

Documents that mention this clinical trial

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
https://doi.org/10.1136/jitc-2023-006755

Documents that mention this clinical trial

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499

Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms
https://doi.org/10.1136/jitc-2025-013285

Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761

Specific recognition of an <i>FGFR2</i> fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma
https://doi.org/10.1136/jitc-2022-006303

Utilization of primary tumor samples for cancer neoantigen discovery
https://doi.org/10.1136/jitc-2024-010993

Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes
https://doi.org/10.1136/jitc-2023-008645

Deregulation of HLA-I in cancer and its central importance for immunotherapy
https://doi.org/10.1136/jitc-2021-002899

Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
https://doi.org/10.1136/jitc-2021-002595

1216 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
https://doi.org/10.1136/jitc-2023-sitc2023.1216

184 Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers
https://doi.org/10.1136/jitc-2021-sitc2021.184

Documents that mention this clinical trial

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499

Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes
https://doi.org/10.1136/jitc-2021-003082

Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
https://doi.org/10.1136/jitc-2021-002723

Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-007218

Documents that mention this clinical trial

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499

Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma
https://doi.org/10.1136/jitc-2023-006822

Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes
https://doi.org/10.1136/jitc-2021-003082

34th Annual Meeting &amp; Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1

CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling
https://doi.org/10.1136/jitc-2021-003750

An update on emerging drugs in osteosarcoma: towards tailored therapies?
https://doi.org/10.1080/14728214.2019.1654455

Documents that mention this clinical trial

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
https://doi.org/10.1136/jitc-2019-000404

Documents that mention this clinical trial

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499

458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)
https://doi.org/10.1136/jitc-2021-sitc2021.458

492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers
https://doi.org/10.1136/jitc-2021-sitc2021.492

Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
https://doi.org/10.1136/jitc-2021-002723

1488 A multicenter phase 2 trial of lifileucel plus pembrolizumab in patients with checkpoint inhibitor-naive metastatic NSCLC: updated results
https://doi.org/10.1136/jitc-2024-sitc2024.1488

The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420

Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.
https://doi.org/10.1200/jco.2024.42.16_suppl.9505

Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-007218

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
https://doi.org/10.1136/jitc-2020-000668